Cyclo Therapeutics (CYTH) Stock Forecast, Price Target & Predictions
CYTH Stock Forecast
Cyclo Therapeutics stock forecast is as follows: an average price target of $0.95 (represents a 31.94% upside from CYTH’s last price of $0.72) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CYTH Price Target
The average price target for Cyclo Therapeutics (CYTH) is $0.95 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $0.95 to $0.95. This represents a potential 31.94% upside from CYTH's last price of $0.72.
CYTH Analyst Ratings
According to 5 Wall Street analysts, Cyclo Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CYTH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Cyclo Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Lucas Ward | Ascendiant | $0.95 | $0.78 | 21.79% | 31.94% |
The latest Cyclo Therapeutics stock forecast, released on Aug 26, 2024 by Lucas Ward from Ascendiant, set a price target of $0.95, which represents a 21.79% increase from the stock price at the time of the forecast ($0.78), and a 31.94% increase from CYTH last price ($0.72).
Cyclo Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $0.95 | $0.95 |
| Last Closing Price | $0.72 | $0.72 | $0.72 |
| Upside/Downside | -100.00% | 31.94% | 31.94% |
In the current month, the average price target of Cyclo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cyclo Therapeutics's last price of $0.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 26, 2024 | Ascendiant | Buy | Buy | Hold |
| Aug 23, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Sep 27, 2023 | Morgan Stanley | - | Underweight | Downgrade |
| Sep 27, 2023 | Maxim Group | - | Buy | Upgrade |
| Mar 21, 2023 | Bernstein | - | Market Perform | Initialise |
Cyclo Therapeutics's last stock rating was published by Ascendiant on Aug 26, 2024. The company gave CYTH a "Buy" rating, the same as its previous rate.
Cyclo Therapeutics Financial Forecast
Cyclo Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $495.48K | $117.12K | $152.41K | $186.80K | $452.17K | $541.89K | $194.90K | $585.12K | $403.92K | $238.59K | $358.13K | $145.59K | $227.36K |
| Avg Forecast | $250.00K | $350.00K | $100.00K | $150.00K | $322.00K | $294.00K | $267.50K | $376.67K | $169.00K | $141.00K | $183.00K | $380.00K | $642.00K | $618.00K | $571.00K | $547.00K | $393.00K | $382.00K | $360.00K | $278.00K | $250.00K | $300.00K |
| High Forecast | $373.50K | $522.90K | $149.40K | $200.00K | $460.00K | $439.23K | $267.75K | $376.83K | $252.48K | $150.91K | $273.40K | $567.72K | $959.14K | $618.00K | $571.00K | $547.00K | $393.00K | $382.00K | $360.00K | $278.00K | $250.00K | $300.00K |
| Low Forecast | $133.11K | $186.36K | $53.24K | $100.00K | $184.00K | $156.54K | $267.25K | $376.50K | $89.98K | $131.09K | $97.44K | $202.33K | $341.83K | $618.00K | $571.00K | $547.00K | $393.00K | $382.00K | $360.00K | $278.00K | $250.00K | $300.00K |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.51% | 0.64% | 0.40% | 0.29% | 0.73% | 0.95% | 0.36% | 1.49% | 1.06% | 0.66% | 1.29% | 0.58% | 0.76% |
Cyclo Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $169.00K, with a low forecast of $89.98K, and a high forecast of $252.48K. CYTH's average Quarter revenue forecast represents a -65.89% decrease compared to the company's last Quarter revenue of $495.48K (Sep 23).
Cyclo Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-4.76M | $-4.62M | $-5.00M | $-4.96M | $-4.24M | $-3.46M | $-3.09M | $-2.79M | $-3.86M | $-3.59M | $-4.03M | $-2.68M | $-2.63M |
| Avg Forecast | $-250.00K | $-350.00K | $-100.00K | $-150.00K | $-322.00K | $-294.00K | $-267.50K | $-376.67K | $-169.00K | $-141.00K | $-183.00K | $-380.00K | $-642.00K | $-618.00K | $-571.00K | $-3.85T | $-393.00K | $-382.00K | $-360.00K | $-278.00K | $-250.00K | $-300.00K |
| High Forecast | $-133.11K | $-186.36K | $-53.24K | $-100.00K | $-184.00K | $-156.54K | $-267.25K | $-376.50K | $-89.98K | $-131.09K | $-97.44K | $-202.33K | $-341.83K | $-618.00K | $-571.00K | $-3.08T | $-393.00K | $-382.00K | $-360.00K | $-278.00K | $-250.00K | $-300.00K |
| Low Forecast | $-373.50K | $-522.90K | $-149.40K | $-200.00K | $-460.00K | $-439.23K | $-267.75K | $-376.83K | $-252.48K | $-150.91K | $-273.40K | $-567.72K | $-959.14K | $-618.00K | $-571.00K | $-4.62T | $-393.00K | $-382.00K | $-360.00K | $-278.00K | $-250.00K | $-300.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | 33.75% | 25.27% | 13.16% | 7.73% | 6.87% | 6.05% | 0.00% | 7.09% | 10.09% | 9.98% | 14.51% | 10.70% | 8.78% |
undefined analysts predict CYTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cyclo Therapeutics's previous annual EBITDA (undefined) of $NaN.
Cyclo Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-4.77M | $-4.64M | $-5.01M | $-4.81M | $-4.25M | $-3.45M | $162.86B | $-2.79M | $-3.86M | $-3.60M | $-4.04M | $-2.68M | $-2.64M |
| Avg Forecast | $-5.46M | $-5.03M | $-5.75M | $-3.56M | $-4.69M | $-4.50M | $-4.45M | $-5.55M | $-6.03M | $-7.76M | $-14.08M | $-12.07M | $-7.18M | $-10.60M | $-9.74M | $-3.64T | $-10.31M | $-10.02M | $-18.90M | $-11.17M | $-5.73M | $-28.64M |
| High Forecast | $-2.14M | $-1.97M | $-2.25M | $-2.08M | $-4.20M | $-1.77M | $-1.75M | $-2.18M | $-2.37M | $-3.04M | $-5.52M | $-4.73M | $-2.82M | $-10.60M | $-9.74M | $-2.91T | $-10.31M | $-10.02M | $-18.90M | $-11.17M | $-5.73M | $-28.64M |
| Low Forecast | $-8.96M | $-8.26M | $-9.44M | $-5.04M | $-4.94M | $-7.39M | $-7.31M | $-9.12M | $-9.91M | $-12.74M | $-23.12M | $-19.82M | $-11.79M | $-10.60M | $-9.74M | $-4.37T | $-10.31M | $-10.02M | $-18.90M | $-11.17M | $-5.73M | $-28.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.62% | 0.33% | 0.41% | 0.67% | 0.40% | 0.35% | -0.04% | 0.27% | 0.39% | 0.19% | 0.36% | 0.47% | 0.09% |
Cyclo Therapeutics's average Quarter net income forecast for Jun 22 is $-9.74M, with a range of $-9.74M to $-9.74M. CYTH's average Quarter net income forecast represents a -100.01% decrease compared to the company's last Quarter net income of $162.86B (Mar 22).
Cyclo Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $1.53M | $1.28M | $1.75M | $1.95M | $1.80M | $2.04M | $2.02M | $1.86M | $2.40M | $1.16M | $1.10M | $1.57M | $895.24K |
| Avg Forecast | $1.13M | $1.58M | $450.90K | $676.36K | $1.45M | $1.33M | $1.21M | $1.70M | $762.03K | $635.77K | $825.15K | $1.71M | $2.89M | $2.53M | $2.34M | $2.24M | $1.61M | $1.57M | $1.48M | $1.14M | $1.02M | $1.23M |
| High Forecast | $1.68M | $2.36M | $673.65K | $901.81K | $2.07M | $1.98M | $1.21M | $1.70M | $1.14M | $680.45K | $1.23M | $2.56M | $4.32M | $2.53M | $2.34M | $2.24M | $1.61M | $1.57M | $1.48M | $1.14M | $1.02M | $1.23M |
| Low Forecast | $600.21K | $840.30K | $240.08K | $450.90K | $829.66K | $705.85K | $1.21M | $1.70M | $405.74K | $591.10K | $439.35K | $912.32K | $1.54M | $2.53M | $2.34M | $2.24M | $1.61M | $1.57M | $1.48M | $1.14M | $1.02M | $1.23M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.40% | 1.55% | 1.02% | 0.67% | 0.71% | 0.87% | 0.90% | 1.16% | 1.53% | 0.79% | 0.96% | 1.53% | 0.73% |
Cyclo Therapeutics's average Quarter SG&A projection for Dec 23 is $762.03K, based on 1 Wall Street analysts, with a range of $405.74K to $1.14M. The forecast indicates a -50.16% fall compared to CYTH last annual SG&A of $1.53M (Sep 23).
Cyclo Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.29 | $-0.33 | $-0.46 | $-0.76 | $-0.50 | $-0.41 | $19.36K | $-0.43 | $-0.60 | $-0.56 | $-0.76 | $-0.50 | $-2.18 |
| Avg Forecast | $-0.19 | $-0.17 | $-0.20 | $-0.12 | $-0.16 | $-0.16 | $-0.15 | $-0.19 | $-0.21 | $-0.27 | $-0.49 | $-0.42 | $-0.25 | $-0.37 | $-0.34 | $-0.33 | $-0.36 | $-0.35 | $-0.66 | $-0.39 | $-0.20 | $-1.00 |
| High Forecast | $-0.07 | $-0.07 | $-0.08 | $-0.07 | $-0.15 | $-0.06 | $-0.06 | $-0.08 | $-0.08 | $-0.11 | $-0.19 | $-0.16 | $-0.10 | $-0.37 | $-0.34 | $-0.33 | $-0.36 | $-0.35 | $-0.66 | $-0.39 | $-0.20 | $-1.00 |
| Low Forecast | $-0.31 | $-0.29 | $-0.33 | $-0.18 | $-0.17 | $-0.26 | $-0.25 | $-0.32 | $-0.34 | $-0.44 | $-0.80 | $-0.69 | $-0.41 | $-0.37 | $-0.34 | $-0.33 | $-0.36 | $-0.35 | $-0.66 | $-0.39 | $-0.20 | $-1.00 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.07% | 0.67% | 1.10% | 3.04% | 1.35% | 1.21% | -58670.58% | 1.19% | 1.71% | 0.85% | 1.95% | 2.51% | 2.18% |
According to 1 Wall Street analysts, Cyclo Therapeutics's projected average Quarter EPS for Jun 22 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -100.00% decrease compared to CYTH previous annual EPS of $19.36K (Mar 22).
Cyclo Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ASRT | Assertio | $0.84 | $2.88 | 242.86% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.02 | $11.67 | 190.30% | Buy |
| AQST | Aquestive Therapeutics | $4.64 | $10.25 | 120.91% | Buy |
| CYTH | Cyclo Therapeutics | $0.72 | $0.95 | 31.94% | Buy |
| ITCI | Intra-Cellular Therapies | $82.47 | $94.50 | 14.59% | Buy |
| AMRX | Amneal Pharmaceuticals | $8.33 | $9.00 | 8.04% | Buy |
| LFCR | Lifecore Biomedical | $6.43 | $6.50 | 1.09% | Buy |
| PAHC | Phibro Animal Health | $24.11 | $18.67 | -22.56% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $3.22 | $0.01 | -99.69% | Buy |